Immune Pharmaceuticals (IMNP) & Corcept Therapeutics (CORT) Critical Survey

Immune Pharmaceuticals (NASDAQ: IMNP) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Immune Pharmaceuticals and Corcept Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Pharmaceuticals N/A N/A -$32.66 million ($3.00) -0.22
Corcept Therapeutics $81.32 million 29.20 $8.14 million $0.29 71.76

Corcept Therapeutics has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Immune Pharmaceuticals and Corcept Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 1 0 3.00
Corcept Therapeutics 0 0 3 0 3.00

Immune Pharmaceuticals presently has a consensus target price of $3.00, suggesting a potential upside of 353.86%. Corcept Therapeutics has a consensus target price of $23.33, suggesting a potential upside of 12.13%. Given Immune Pharmaceuticals’ higher probable upside, equities analysts plainly believe Immune Pharmaceuticals is more favorable than Corcept Therapeutics.

Insider and Institutional Ownership

1.6% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.6% of Corcept Therapeutics shares are owned by institutional investors. 3.9% of Immune Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Immune Pharmaceuticals and Corcept Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Corcept Therapeutics 27.28% 58.17% 41.48%

Volatility and Risk

Immune Pharmaceuticals has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.


Corcept Therapeutics beats Immune Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation’s Abraxane) to treat patients with solid-tumor cancers.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit